Clinical trials: Cancer Therapy-related Cardiovascular Toxicity
Ovarian Cancer
Exercise Preconditioning in Ovarian Cancer
The purpose of this study is to determine if exercise preconditioning can mitigate the off target effects of chemotherapy treatment on measures of cardiovascular function, peripheral neuropathy, and quality of life.
- Trial name
- NCT05029154
- Testing
- High intensity interval exercise, Attention control
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Virginia
Toxicity Due to Chemotherapy, Cardiovascular Morbidity
Investigating Cardiovascular Adverse Events Related to Cancer Treatment
Cisplatin, anthracyclines, bleomycin and trastuzumab can cause severe cardiovascular or pulmonary toxicity. Why some patients are susceptible to extreme toxicity of cancer treatment is largely unknown.
- Conditions
- Toxicity Due to Chemotherapy, Cardiovascular Morbidity, Cancer, Treatment-Related
- Trial name
- InvestiCAT (NCT03199300)
- Testing
- Anthracyclines, Trastuzumab, Cisplatin
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Cardiac Toxicity, Inflammatory Breast Cancer
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Randomized phase III trial to compare the effectiveness of combination chemotherapy, surgery, and radiation therapy with or without dexrazoxane and trastuzumab in treating women who have stage IIIA, stage IIIB or stage IV breast…
- Conditions
- Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00016276
- Testing
- dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide
- Where
- United States
- Volunteers
- 396 people
- Sponsor
- National Cancer Institute (NCI)
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00019864
- Testing
- filgrastim, cisplatin, dexrazoxane hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Neoplasm, Breast
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020.
- Conditions
- Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents
- Trial name
- NCT05465031
- Testing
- Sacubitril-valsartan
- Where
- 4 sites in Poland
- Volunteers
- 600 people
- Sponsor
- Silesian Centre for Heart Diseases
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy.
- Trial name
- NCT00003070
- Testing
- enalapril maleate, quality-of-life assessment
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 13 people
- Sponsor
- Children's Oncology Group